CA2128528A1 - Process for typing of hcv isolates - Google Patents
Process for typing of hcv isolatesInfo
- Publication number
- CA2128528A1 CA2128528A1 CA002128528A CA2128528A CA2128528A1 CA 2128528 A1 CA2128528 A1 CA 2128528A1 CA 002128528 A CA002128528 A CA 002128528A CA 2128528 A CA2128528 A CA 2128528A CA 2128528 A1 CA2128528 A1 CA 2128528A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleotide
- hcv
- type
- extending
- figures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
Abstract
2128528 9412670 PCTABS00032 The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position -291 to nucleotide at position -66 of the 5' untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes; detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be identified.
Claims (23)
1. Use of at least one probe, with said probe being (i) capable of hybridizing to a genotype specific target region, present in an analyte strand, in the domain extending from the nucleotides at positions -291 to -66 of the 5' untranslated region of one of the HCV isolates, or with said probe being (ii) complementary to any of the above-defined probes, for genotyping HCV isolates present in a biological sample.
2. Process for genotyping HCV isolates present in a biological sample;
comprising the steps of:
- contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe, with said probe being (i) capable of hybridizing to a region in the domain extending from nucleotides at positions -291 to -66 of the 5' untranslated region of one of the HCV isolates, or with said probe being (ii) ccmplementary to any of the above-defined probes, and, - detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be identified.
comprising the steps of:
- contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe, with said probe being (i) capable of hybridizing to a region in the domain extending from nucleotides at positions -291 to -66 of the 5' untranslated region of one of the HCV isolates, or with said probe being (ii) ccmplementary to any of the above-defined probes, and, - detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be identified.
3. Process according to claim 2, wherein a set of probes comprising at least two probes, is used.
4. Process according to anyone of claims 2 or 3, wherein the probe used targets a region of at least 5 nucleotides in one of the following domains:
a) the one extending from nucleotide at position -293 to nucleotide at position -278 (in Figures 2 and 4), b) the one extending from nucleotide at position -275 to nucleotide at position -260 (in Figures 2 and 4), c) the one extending from nucleotide at position -253 to nucleotide at position -238 (in Figures 2 and 4), d) the one extending from nucleotide at position -244 to nucleotide at position -229 (in Figures 2 and 4), e) the one extending from nucleotide at position -238 to nucleotide at position -223 (in Figures 2 and 4), f) the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4), g) the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4), h) the one extending from nucleotide at position -83 to nucleotide at position -68 (in Figures 2 and 4), i) the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4), j) the one extending from nucleotide at position -146 to nucleotide at position -130.
a) the one extending from nucleotide at position -293 to nucleotide at position -278 (in Figures 2 and 4), b) the one extending from nucleotide at position -275 to nucleotide at position -260 (in Figures 2 and 4), c) the one extending from nucleotide at position -253 to nucleotide at position -238 (in Figures 2 and 4), d) the one extending from nucleotide at position -244 to nucleotide at position -229 (in Figures 2 and 4), e) the one extending from nucleotide at position -238 to nucleotide at position -223 (in Figures 2 and 4), f) the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4), g) the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4), h) the one extending from nucleotide at position -83 to nucleotide at position -68 (in Figures 2 and 4), i) the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4), j) the one extending from nucleotide at position -146 to nucleotide at position -130.
5. Process according to claim 4, wherein for each type or subtype of HCV
to be determined, a set of two different probes or a mixture of two different probes is used, each probe of the set or of the mixture targeting respecffvely different regions respectively chosen from among the following list of pairs of domains as defined in claim 4:
* the one extending fiom nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -141 to nucleotide at position -11 7 (in Figures 2 and 4), * the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4), * the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4), * the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -83 to nucleotide at position -68 (,in Figures 2 and 4), * the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4) and the one extending firom nucleotide at position -83 to nucleotide at position -68 (in Figures 2 and 4), * the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4), * the one extending from nucleotide at position -132 to nucleotide at position -117 (in Figures 2 and 4) and the one extending f~om nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4), * the one extending from nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4).
to be determined, a set of two different probes or a mixture of two different probes is used, each probe of the set or of the mixture targeting respecffvely different regions respectively chosen from among the following list of pairs of domains as defined in claim 4:
* the one extending fiom nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -141 to nucleotide at position -11 7 (in Figures 2 and 4), * the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4), * the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4), * the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -83 to nucleotide at position -68 (,in Figures 2 and 4), * the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4) and the one extending firom nucleotide at position -83 to nucleotide at position -68 (in Figures 2 and 4), * the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4), * the one extending from nucleotide at position -132 to nucleotide at position -117 (in Figures 2 and 4) and the one extending f~om nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4), * the one extending from nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4).
6. Probe having a sequence such that it targets at least one of the following sequences:
wherein Y represents T or C
K represents G or T
and R represents G or A
- or the corresponding sequence wherein T has been replaced by U, - or the sequences which are complementary to the above-defined sequences.
wherein Y represents T or C
K represents G or T
and R represents G or A
- or the corresponding sequence wherein T has been replaced by U, - or the sequences which are complementary to the above-defined sequences.
7. Set of two probes or mixtures of two probes wherein each of the two probes respectively targets different regions chosen from among the following list of pairs of domains as defined in claim 4:
* the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4), * the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4), * the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4), * the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -83 to nucleotide at position -68 (in Figures 2 and 4).
* the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4) and the one extending from nucleotide at position -83 to nucleotide at position -68 (in Figures 2 and 4).
* the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4), * the one extending from nucleotide at position -132 to nucleotide at position -117 (in Figures 2 and 4) and the one extending from nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4), * the one extending from nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4).
* the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4), * the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4), * the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4), * the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -83 to nucleotide at position -68 (in Figures 2 and 4).
* the one extending from nucleotide at position -141 to nucleotide at position -117 (in Figures 2 and 4) and the one extending from nucleotide at position -83 to nucleotide at position -68 (in Figures 2 and 4).
* the one extending from nucleotide at position -170 to nucleotide at position -155 (in Figures 2 and 4) and the one extending from nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4), * the one extending from nucleotide at position -132 to nucleotide at position -117 (in Figures 2 and 4) and the one extending from nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4), * the one extending from nucleotide at position -146 to nucleotide at position -130 (in Figures 2 and 4) and the one extending from nucleotide at position -103 to nucleotide at position -88 (in Figures 2 and 4).
8. Process according to any one of claims 2 to 7, for genotyping HCV
isolates belonging to at least one of the following HCV types: HCV type 1, -HCV
type 2, HCV type 3, HCV type 4, HCV type 5, HCV type 6, from a biological sample liable to contain it, comprising the steps of:
- contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe being (i) capable of hybridizing to a region being in the domain extending from nucleotide at position -291 to nucleotide at position -66 of the 5' untranslated region of HCV isolates or with said probe being (ii) complementary to the above-defined probes, and,;
- detecting the complexes possibly formed between said probe and the target region, and, - inferring the HCV types present from the observed hybridization patterns
isolates belonging to at least one of the following HCV types: HCV type 1, -HCV
type 2, HCV type 3, HCV type 4, HCV type 5, HCV type 6, from a biological sample liable to contain it, comprising the steps of:
- contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe being (i) capable of hybridizing to a region being in the domain extending from nucleotide at position -291 to nucleotide at position -66 of the 5' untranslated region of HCV isolates or with said probe being (ii) complementary to the above-defined probes, and,;
- detecting the complexes possibly formed between said probe and the target region, and, - inferring the HCV types present from the observed hybridization patterns
9. Process according to claim g, for genotyping HCV isolates as belonging to at least one of the following HCV types: HCV type 1, HCV type 2, HCV type 3 or HCV type 4, HCV type 5, HCV type 6, wherein the probes used are able to target at least one of the following target regions, or said regions wherein T has been replaced by U, or the regions which are complementary to the above-said regions:
for HCV type I and 6:
for HCV type 1: for HCV type 2: for HCV type 3: for HCV type 4 and 5: for HCV type 4: for HCV type 4, 3c and 3b: for HCV type 4 and 3b: for HCV type 4: for HCV type 5: for HCV type 6: wherein Y represents C or T, and K represents G or T, or the probes used are a set of two probes chosen from among the above-defined probes.
for HCV type I and 6:
for HCV type 1: for HCV type 2: for HCV type 3: for HCV type 4 and 5: for HCV type 4: for HCV type 4, 3c and 3b: for HCV type 4 and 3b: for HCV type 4: for HCV type 5: for HCV type 6: wherein Y represents C or T, and K represents G or T, or the probes used are a set of two probes chosen from among the above-defined probes.
10. Process according to claim 9, also comprising the discrimination and classification of subtypes of HCV, wherein besides at least one probe capable of hybridising with a certain type of HCV as defined in claim 9, at least one of the probes targeting the following target regions is used, or said regions wherein T is replaced by U, or said regions which are complementary to the above defined regions, for HCV type 1, subtype 1a:
for HCV type 1, subtype 1b:
wherein Y represents C or T, for HCV type 2, subtype 2a:
wherein R represents A or G, for HCV type 2, subtype 2b:
for HCV type 2, subtype 2c:
for HCV type 3, subtype 3a:
wherein K represents G or T, for HCV type 3, subtype 3b:
for HCV type 3, subtype 3c:
for HCV type 4, subtype 4a or 4d:
for type 4, subtype 4b :
for type 4, subtype 4c : for type 4, subtype 4e : for type 4, subtype 4f : for type 4, subtype 4g (provisional): for type 4, subtype 4h (provisional): or the probes used are a set of two probes chosen from among the defined probes, and when there are only two subtypes of a type, these above-mentioned probes being liable to determine, by exclusion, the subtype deduced from the fact that they do not target one of the above-mentioned regions.
for HCV type 1, subtype 1b:
wherein Y represents C or T, for HCV type 2, subtype 2a:
wherein R represents A or G, for HCV type 2, subtype 2b:
for HCV type 2, subtype 2c:
for HCV type 3, subtype 3a:
wherein K represents G or T, for HCV type 3, subtype 3b:
for HCV type 3, subtype 3c:
for HCV type 4, subtype 4a or 4d:
for type 4, subtype 4b :
for type 4, subtype 4c : for type 4, subtype 4e : for type 4, subtype 4f : for type 4, subtype 4g (provisional): for type 4, subtype 4h (provisional): or the probes used are a set of two probes chosen from among the defined probes, and when there are only two subtypes of a type, these above-mentioned probes being liable to determine, by exclusion, the subtype deduced from the fact that they do not target one of the above-mentioned regions.
11. Process according to anyone of claims 2 to 10, wherein the HCV
types or subtypes to be differentiated are identified by means of universal probes for HCV, such as the ones targeting one of the following regions:
types or subtypes to be differentiated are identified by means of universal probes for HCV, such as the ones targeting one of the following regions:
12. Process according to anyone of claim 2 to 11 wherein the hybridisation step is preceeded by an amplification step of the deoxyribonucleotide orribonucleotide containing the region to target, advantageously comprising the following steps:
- contacting the biological sample liable to contain the isolate to be typed or subtyped with a set of primers, flanking the region to target, with said primers being complementary to conserved regions of the HCV genome, and preferably primers being complementary to the 5' untranslated conserved regions of the HCV genome, with said primers preferably having at least 15 contiguous nucleotides. with said contiguous nucleotides being respectively complementary to sequences chosen from the region extending from nucleotide -341 to nucleotide -171 and from the region extending from nucleotide -67 to nucleotide -1(, of figures 2 and 4), - amplifying the target region, for instance via a polymerase chain reaction by means of the above-mentioned set of primers and possibly incorporating a label, such as digoxigenin or biotin into the amplified target sequence, with said amplifying being repeated between 20 and 80 times, advantageously between 30 and 50 times.
- contacting the biological sample liable to contain the isolate to be typed or subtyped with a set of primers, flanking the region to target, with said primers being complementary to conserved regions of the HCV genome, and preferably primers being complementary to the 5' untranslated conserved regions of the HCV genome, with said primers preferably having at least 15 contiguous nucleotides. with said contiguous nucleotides being respectively complementary to sequences chosen from the region extending from nucleotide -341 to nucleotide -171 and from the region extending from nucleotide -67 to nucleotide -1(, of figures 2 and 4), - amplifying the target region, for instance via a polymerase chain reaction by means of the above-mentioned set of primers and possibly incorporating a label, such as digoxigenin or biotin into the amplified target sequence, with said amplifying being repeated between 20 and 80 times, advantageously between 30 and 50 times.
13. Process according to claim 12, wherein the amplification consists of a double PCR step, each step involving a specific set of primers, with (the) said first step involving outer primers selected from the region extending from nucleotide -341 to nucleotide -186 and from the region extending from nucleotide -52 to nucleotide -1, and more particularly the following set:
or their complements, wherein W represents A or T, and with the second step involving nested primers selected from the region extending from nucleotide - 326 to nucleotide -171 and from the region extending from nucleotide -68 to nucleotide -I and, more particularly the following set:
wherein R represents A or G and Y represents T or C, or their complements.
or their complements, wherein W represents A or T, and with the second step involving nested primers selected from the region extending from nucleotide - 326 to nucleotide -171 and from the region extending from nucleotide -68 to nucleotide -I and, more particularly the following set:
wherein R represents A or G and Y represents T or C, or their complements.
14. Process for the simultaneous genotyping of all HCV isolates contained in a biological sample according to anyone of claims to 2 to 13, comprising the step of contacting one of the following elements:
- either said biological sample in which the genetic material is made available for hybridization, - or the purified genetic material contained in said biological sample, - or single copies derived from the purified genetic material, - or amplified copies derived from the purified genetic material, with a solid support on which probes according to anyone of claims 2 to 13 have been previously immobilized.
- either said biological sample in which the genetic material is made available for hybridization, - or the purified genetic material contained in said biological sample, - or single copies derived from the purified genetic material, - or amplified copies derived from the purified genetic material, with a solid support on which probes according to anyone of claims 2 to 13 have been previously immobilized.
15. Process according to any one of claims 2 to 14, comprising the steps of contacting anyone of the probes according to anyone of claims 2 to 14, with one of the following elements:
- either a biological sample in which the genetic material is made available for hybridization, - or the purified genetic material contained in said biological sample, - or a single copy derived from the purified genetic materail, - or an amplified copy derived from the purified genetic material, with said elements being previously immobilized on a support.
- either a biological sample in which the genetic material is made available for hybridization, - or the purified genetic material contained in said biological sample, - or a single copy derived from the purified genetic materail, - or an amplified copy derived from the purified genetic material, with said elements being previously immobilized on a support.
16. Process for detecting and identifying novel HCV types or subtypes, different from the known types or subtypes, comprising the steps of:
- determing to which known types or subtypes, the HCV
isolates present in the biological sample belong to, according to the process asdefined in claim 2, possibly with said biological sample being previously determined as containing HCV, possibly by means of HCV antigen or antibody assays or with a universal probe for HCV, such as those defined in claim 11, - in the case of observing a sample which does not hybridize positively with at least one of the probes able to target the regions chosen from any of the domains as defined in claim 4, sequencing the complete genome of the HCV type present in the sample, or, alternatively sequencing that (the) portion(s) of the 5' untranslated region of the sample corresponding to a new type and/or subtype to be determined.
- determing to which known types or subtypes, the HCV
isolates present in the biological sample belong to, according to the process asdefined in claim 2, possibly with said biological sample being previously determined as containing HCV, possibly by means of HCV antigen or antibody assays or with a universal probe for HCV, such as those defined in claim 11, - in the case of observing a sample which does not hybridize positively with at least one of the probes able to target the regions chosen from any of the domains as defined in claim 4, sequencing the complete genome of the HCV type present in the sample, or, alternatively sequencing that (the) portion(s) of the 5' untranslated region of the sample corresponding to a new type and/or subtype to be determined.
17. Process for the detection and identification of novel HCV types and/or subtypes, present in a biological sample, which are different from type 1, type 2, type 3, type 4, type 5 and type 6, in the case of identifying a novel type; and which are different from subtypes la and lb for a type 1 HCV isolate, from subtypes 2a and 2b for a type 2 isolate, from subtypes 3a 3b, and 3c for a type 3 isolate, from subtypes 4a, 4b, 4c 4d, 4e, 4f, 4g(provisional) and 4h(provisional) for a type 4 isolate, in the case of identifying a novel subtype and comprising the steps of:
- determining to which known type(s) or subtype(s) the HCV isolate(s) present in the biological sample to be analyzed belongs, according to the process according to anyone of claims 2 to 14, possibly with said biological sample being previously determined as containing HCV, possibly by means of HCV antigen or antibody assays or with a universal probe for HCV such as the one defined in claim I 1, - in the case of observing a sample which does not hybridize to at least one of the probes able to target the regions chosen from any of the type specific or subtype specific domains æ defined in claims 9 and 10, moreparticulary not hybridizing with SEQ ID NO 5, 28 and 6 for type 1, with SEQ ID
NO 8 to 12 or 22 to 26 and 32 to 34 for type 2, with SEQ ID NO 13, 14, 36, 21 or54 for type 3, and with SEQ ID NO 17, 18, 19, 37 to 43, 49, 50 and 53 for type 4;
and with SEQ ID MO 7 and 30 for subtype lb, with SEQ ID NO 31 for subtype la, with SEQ ID NO 9, 10, 22 or 24 for subtype 2a, with SEQ ID NO 11, 12, 23 or 25 for subtype 2b, with SEQ ID NO 33 or 34 for subtype 2c, with SEQ ID NO 13, 14 or 35 for subtype 3a, with SEQ ID NO 38, 21 and 19 for subtype 3b, 4a or 4d, with SEQ ID NO 38 or 41 for subtype 4b; with SEQ ID NO 42 or 43 for subtype 4c;
with SEQ ID NO 39, 40, or 41 for subtype 4e, with SEQ ID NQ 51, 38, 19 or 7;
for subtype 4f; with SEQ ID NO 49 or 50 for the putative subtype 4h; with SEQ
ID NO 50 or 53 for the putative subtype 4g, sequencing the complete genome of the HCV type present in the sample, or, alternatively sequencing that (the) porton(s) of the S' untranslated region of the sample corresponding to a new type and/or subtype to be determined
- determining to which known type(s) or subtype(s) the HCV isolate(s) present in the biological sample to be analyzed belongs, according to the process according to anyone of claims 2 to 14, possibly with said biological sample being previously determined as containing HCV, possibly by means of HCV antigen or antibody assays or with a universal probe for HCV such as the one defined in claim I 1, - in the case of observing a sample which does not hybridize to at least one of the probes able to target the regions chosen from any of the type specific or subtype specific domains æ defined in claims 9 and 10, moreparticulary not hybridizing with SEQ ID NO 5, 28 and 6 for type 1, with SEQ ID
NO 8 to 12 or 22 to 26 and 32 to 34 for type 2, with SEQ ID NO 13, 14, 36, 21 or54 for type 3, and with SEQ ID NO 17, 18, 19, 37 to 43, 49, 50 and 53 for type 4;
and with SEQ ID MO 7 and 30 for subtype lb, with SEQ ID NO 31 for subtype la, with SEQ ID NO 9, 10, 22 or 24 for subtype 2a, with SEQ ID NO 11, 12, 23 or 25 for subtype 2b, with SEQ ID NO 33 or 34 for subtype 2c, with SEQ ID NO 13, 14 or 35 for subtype 3a, with SEQ ID NO 38, 21 and 19 for subtype 3b, 4a or 4d, with SEQ ID NO 38 or 41 for subtype 4b; with SEQ ID NO 42 or 43 for subtype 4c;
with SEQ ID NO 39, 40, or 41 for subtype 4e, with SEQ ID NQ 51, 38, 19 or 7;
for subtype 4f; with SEQ ID NO 49 or 50 for the putative subtype 4h; with SEQ
ID NO 50 or 53 for the putative subtype 4g, sequencing the complete genome of the HCV type present in the sample, or, alternatively sequencing that (the) porton(s) of the S' untranslated region of the sample corresponding to a new type and/or subtype to be determined
18. A method for determining the type(s) as well as the subtypes(s) of HCV, and/or HIV, and/or HBV and/or HTLV present in a biological sample, which comprises the steps of:
- providing * at least one of the probes æ defined in any of claims 1 to 8, preferably the probes æ defined in claims 9 and IQ enabling the genotyping (typing and/or subtyping) of HCV, and at least one of the following probes:
* probes capable of detecting oligonucleotides of HIV
types 1 and/or 2 which can be present in said biological sample, and/or * probes capable of detecting oligonucleotides of HBV
subtypes and/or surface antigen (sAg) mutants and/or core antigen (cAg) mutants which can be present in said biological sample and/or * probes capable of detecting oligonucleotides of HTLV-I
and/or HTLV-II suspected to be in the biological sample, - possibly providing a set of primers as defined in claims 12 or 13, as well at least one of the following primers: sets of primers to respectively amplify HIV, and/or HBV and/or HTLV oligonucleotides, by means of PCR
reaction and amplifying the oligonucleotides of HCV, and either HBV and/or HIV
and/ or HTLV possibly present in the biological sample, - contacting * the biological sample in which the genetic material is made available for hybridization, * or the purified genetic material contained in said biological sample, * or single copies derived from the purified genetic material, * or amplified copies derived from the purified genetic material, with the probes defined above under conditions which allow hybridization between the probes and the target sequences of isolates of HCV and at least one of the following viruses: HBV and/or HIV and/or HTLV, - detecting the complexes possibly formed between the probes used and the target regions possibly present in the biological sample.
- providing * at least one of the probes æ defined in any of claims 1 to 8, preferably the probes æ defined in claims 9 and IQ enabling the genotyping (typing and/or subtyping) of HCV, and at least one of the following probes:
* probes capable of detecting oligonucleotides of HIV
types 1 and/or 2 which can be present in said biological sample, and/or * probes capable of detecting oligonucleotides of HBV
subtypes and/or surface antigen (sAg) mutants and/or core antigen (cAg) mutants which can be present in said biological sample and/or * probes capable of detecting oligonucleotides of HTLV-I
and/or HTLV-II suspected to be in the biological sample, - possibly providing a set of primers as defined in claims 12 or 13, as well at least one of the following primers: sets of primers to respectively amplify HIV, and/or HBV and/or HTLV oligonucleotides, by means of PCR
reaction and amplifying the oligonucleotides of HCV, and either HBV and/or HIV
and/ or HTLV possibly present in the biological sample, - contacting * the biological sample in which the genetic material is made available for hybridization, * or the purified genetic material contained in said biological sample, * or single copies derived from the purified genetic material, * or amplified copies derived from the purified genetic material, with the probes defined above under conditions which allow hybridization between the probes and the target sequences of isolates of HCV and at least one of the following viruses: HBV and/or HIV and/or HTLV, - detecting the complexes possibly formed between the probes used and the target regions possibly present in the biological sample.
19. Solid support, particularly a membrane strip containing, on known locations of its surface, the following probes, or their complements, or the above-said probes wherein T has been replaced by U:
-SEQ ID NO 5,NO 6,NO 7,NO 8,NO 9,NO 10,NO 11 NO
12,NO 13,NO 14,NO 15,NO 16,NO 17,NO 18,NO 19,NO 20,NO 21,NO 22, NO 23,NO 24,NO 25,NO 26,NO 27,NO 28 to NO 54 and SEQ ID NO 93 to 96, according to claims 9 and 10, as well as a control to determine if there is hybridization between these probe and the ribo or deoxyribonucleotide strands ofHCV, liable to be contained in a biological sample in which HCV isolates are to be discriminated.
-SEQ ID NO 5,NO 6,NO 7,NO 8,NO 9,NO 10,NO 11 NO
12,NO 13,NO 14,NO 15,NO 16,NO 17,NO 18,NO 19,NO 20,NO 21,NO 22, NO 23,NO 24,NO 25,NO 26,NO 27,NO 28 to NO 54 and SEQ ID NO 93 to 96, according to claims 9 and 10, as well as a control to determine if there is hybridization between these probe and the ribo or deoxyribonucleotide strands ofHCV, liable to be contained in a biological sample in which HCV isolates are to be discriminated.
20. Kit for the in vitro discrimination of any isolate of HCV, with said kit containing - means to identify the presence of HCV isolate, - at least one probe as defined in claim 1, - a buffer or components necessary for producing the buffer enabling hybridization reation between these probes and the DNAs and/or RNAs of HCV isolates to be carried out, - when appropriate, means for detecting the hybrids resulting from the preceding hybridization.
21. Kit for typing at least one HCV isolate, from a biological sample liable to contain it, and for classifying it acccording to the HCV type and subtype, with said kit containing - possibly one probe as defined in claim 1 l, - at least one probe selected among any of those according to claims 2 to 10, - a buffer or components necessary for producing the buffer enabling hybridization reaction between these probes and the DNAs and/or RNAs of HCV isolates to be carried out;
- when appropriate, means for detecting the hybrids resulting from the preceding hybridization.
- when appropriate, means for detecting the hybrids resulting from the preceding hybridization.
22. Kit for typing HCV isolates belonging to at least one of the following HCV isolates: HCV type 1, HCV type 2, HCV type 3, HCV type 4, HCV type 5, HCV type 6 with said kit containing at least one of the probes according to claim 9, - the buffer or components necessary for producing the buffer enabling hybridization reaction between these probes and the cDNAs and/orRNAs of the above-mentioned HCV isolates to be carried out;
- when appropriate, means for detecting the hybrids resulting from the preceding hybridization.
- when appropriate, means for detecting the hybrids resulting from the preceding hybridization.
23. Kit for the discrimination and classification of HCV types and subtypes, with said kit containing:
- at least one of the probes according to claims 9 or 10, - the buffer or components necessary for producing the buffer enabling hybridization reaction between these probes and the DNAs and/or RNAs of the above-mentioned HCV isolates to be carried out;
- when appropriate, means for detecting the hybrids resulting from the preceding hybridization.
- at least one of the probes according to claims 9 or 10, - the buffer or components necessary for producing the buffer enabling hybridization reaction between these probes and the DNAs and/or RNAs of the above-mentioned HCV isolates to be carried out;
- when appropriate, means for detecting the hybrids resulting from the preceding hybridization.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92.403222.0 | 1992-11-27 | ||
| EP92403222 | 1992-11-27 | ||
| EP93402129 | 1993-08-31 | ||
| EP93.402129.6 | 1993-08-31 | ||
| PCT/EP1993/003325 WO1994012670A2 (en) | 1992-11-27 | 1993-11-26 | Process for typing of hcv isolates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2128528A1 true CA2128528A1 (en) | 1994-06-09 |
| CA2128528C CA2128528C (en) | 2012-02-14 |
Family
ID=26132445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2128528A Expired - Lifetime CA2128528C (en) | 1992-11-27 | 1993-11-26 | Process for typing of hcv isolates |
Country Status (13)
| Country | Link |
|---|---|
| US (8) | US5846704A (en) |
| EP (3) | EP1197568B1 (en) |
| JP (2) | JP4251407B2 (en) |
| AT (2) | ATE179459T1 (en) |
| AU (1) | AU681612B2 (en) |
| CA (1) | CA2128528C (en) |
| DE (2) | DE69324678T2 (en) |
| DK (1) | DK0637342T3 (en) |
| ES (1) | ES2133529T3 (en) |
| GR (1) | GR3030641T3 (en) |
| HK (1) | HK1047961A1 (en) |
| SG (1) | SG46456A1 (en) |
| WO (1) | WO1994012670A2 (en) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0637342T3 (en) * | 1992-11-27 | 1999-11-01 | Innogenetics Nv | Method for typing HCV isolates |
| US7258977B1 (en) * | 1992-11-27 | 2007-08-21 | Innogenetics N.V. | Process for typing of HCV isolates |
| AU6352894A (en) * | 1993-03-05 | 1994-09-26 | Roy J. Mankovitz | Apparatus and method using compressed codes for television program record scheduling |
| US7255997B1 (en) * | 1993-04-27 | 2007-08-14 | N.V. Innogenetics S.A. | Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents |
| US7157226B1 (en) * | 1993-04-27 | 2007-01-02 | Innogenetics S.A. | Sequences of hepatitis C virus genotypes and their use as therapeutic and diagnostic agents |
| US5830635A (en) * | 1995-03-31 | 1998-11-03 | Agnello; Vincent | Method of detecting hepatitis C virus in tissues |
| US20020081577A1 (en) * | 1995-06-06 | 2002-06-27 | Robert L. Kilkuskie | Oligonucleotides speciific for hepatitis c virus |
| BR9704637A (en) * | 1996-01-26 | 1998-06-09 | Innogenetics Nv | Process for detecting drug-induced mutations in the reverse transcription gene |
| ZA973367B (en) | 1996-04-19 | 1997-11-18 | Innogenetics Nv | Method for typing and detecting HBV. |
| FR2750505B1 (en) | 1996-06-27 | 1998-10-16 | Appligene Oncor | PROCESS FOR THE PREPARATION OF ANALYSIS MEDIA FOR CHEMICAL OR BIOLOGICAL SUBSTANCES HAVING ORDERED SET OF REACTION AREAS |
| CA2276462C (en) | 1996-12-31 | 2007-06-12 | Genometrix Incorporated | Multiplexed molecular analysis system apparatus and method |
| US7101672B2 (en) * | 1998-05-05 | 2006-09-05 | Third Wave Technologies, Inc. | Target-dependent reactions using structure-bridging oligonucleotides |
| IL122299A (en) * | 1997-11-25 | 2003-11-23 | Broadcom Corp | Video encoding device |
| US20030096232A1 (en) | 1997-12-19 | 2003-05-22 | Kris Richard M. | High throughput assay system |
| EP1008658A4 (en) * | 1998-05-19 | 2002-08-28 | Lab Molecular Biophotonics | Solid phase for detecting nucleic acid and method for detecting nucleic acid |
| CN101383947B (en) | 1998-07-17 | 2012-08-01 | 联合视频制品公司 | Method for access to and providing programme by remote access link |
| AR020608A1 (en) | 1998-07-17 | 2002-05-22 | United Video Properties Inc | A METHOD AND A PROVISION TO SUPPLY A USER REMOTE ACCESS TO AN INTERACTIVE PROGRAMMING GUIDE BY A REMOTE ACCESS LINK |
| AU2006203092B2 (en) * | 1999-02-03 | 2009-11-12 | Ortho-Clinical Diagnostics, Inc. | Oligonucleotide primers for efficient detection of hepatitis C virus (HCV) and methods of use thereof |
| US6638714B1 (en) * | 1999-02-03 | 2003-10-28 | Ortho-Clinical Diagnostics, Inc. | Oligonucleotide primers for efficient detection of hepatitis C virus (HCV) and methods of use thereof |
| US6623919B1 (en) * | 1999-02-03 | 2003-09-23 | Ortho-Clinical Diagnostics, Inc | Oligonucleotide primers for efficient multiplex detection of hepatitis C virus (HCV) and human immunodeficiency virus (HIV) and methods of use thereof |
| GB0016836D0 (en) | 2000-07-07 | 2000-08-30 | Lee Helen | Improved dipstick assays (1) |
| US6586584B2 (en) | 2001-01-29 | 2003-07-01 | Becton, Dickinson And Company | Sequences and methods for detection of Hepatitis C virus |
| KR100461715B1 (en) * | 2001-03-27 | 2004-12-17 | 가부시끼가이샤 도시바 | Detection of Nucleic Acid Associated with Disease |
| WO2002090572A2 (en) * | 2001-05-09 | 2002-11-14 | Third Wave Technologies, Inc. | Nucleic acid detection in pooled samples |
| US7196183B2 (en) * | 2001-08-31 | 2007-03-27 | Innogenetics N.V. | Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent |
| US7877273B2 (en) * | 2002-01-08 | 2011-01-25 | Fredric David Abramson | System and method for evaluating and providing nutrigenomic data, information and advice |
| GB0200526D0 (en) * | 2002-01-11 | 2002-02-27 | Science And Technology The | Methods |
| FR2855832B1 (en) | 2003-06-03 | 2007-09-14 | Biomerieux Sa | DIAGNOSTIC AND / OR PROGNOSTIC METHOD OF SEPTIC SYNDROME |
| FR2857375B1 (en) | 2003-07-10 | 2007-11-09 | Biomerieux Sa | PROCESS FOR THE DETECTION AND / OR IDENTIFICATION OF STAPHYLOCOCCUS GENE BACTERIA |
| EP1536024B1 (en) * | 2003-08-29 | 2016-08-17 | Fujirebio Europe N.V. | New hepatitis c virus clade and phototype sequences thereof |
| US8124747B2 (en) * | 2003-08-29 | 2012-02-28 | Innogenetics | HCV clade and prototype sequences thereof |
| US7473773B2 (en) * | 2004-01-07 | 2009-01-06 | Third Wave Technologies, Inc. | Determination of hepatitis C virus genotype |
| WO2005098021A1 (en) * | 2004-04-06 | 2005-10-20 | Flinders Technologies Pty. Ltd. | Detecting targets using nucleic acids having both a variable region and a conserved region |
| US8806533B1 (en) | 2004-10-08 | 2014-08-12 | United Video Properties, Inc. | System and method for using television information codes |
| FR2881437B1 (en) | 2005-01-31 | 2010-11-19 | Biomerieux Sa | METHOD FOR THE DIAGNOSIS / PROGNOSIS OF A SEPTIC SYNDROME |
| EP1866445B1 (en) | 2005-03-30 | 2013-10-16 | Labo Bio-Medical Investments B.V. | Identification of beta-papillomavirus dna by type-specific reverse hybridization |
| US20070072211A1 (en) * | 2005-06-30 | 2007-03-29 | Roche Molecular Systems, Inc. | Asymmetric PCR coupled with post-PCR characterization for the identification of nucleic acids |
| WO2007059348A2 (en) * | 2005-11-17 | 2007-05-24 | Third Wave Technologies, Inc. | Compositions and methods for detecting an hcv-1 subtype |
| WO2007087310A2 (en) * | 2006-01-23 | 2007-08-02 | Population Genetics Technologies Ltd. | Nucleic acid analysis using sequence tokens |
| FR2906537A1 (en) | 2006-09-28 | 2008-04-04 | Biomerieux Sa | METHOD FOR IN VITRO DIAGNOSIS OF BRONCHO-PULMONARY CANCER BY DETECTION OF ALTERNATIVE MAJORITY TRANSCRIPTS OF KLK8 GENE ENCODING KALLICREIN 8 AND USE THEREOF FOR THE PROGNOSIS OF SURVIVAL |
| US20110136678A1 (en) | 2006-10-20 | 2011-06-09 | Erwin Sablon | Methodology for analysis of sequence variations within the hcv ns3/4a genomic region |
| US20090325145A1 (en) | 2006-10-20 | 2009-12-31 | Erwin Sablon | Methodology for analysis of sequence variations within the hcv ns5b genomic region |
| US8418206B2 (en) | 2007-03-22 | 2013-04-09 | United Video Properties, Inc. | User defined rules for assigning destinations of content |
| WO2009022939A1 (en) * | 2007-08-09 | 2009-02-19 | Uchrezhdenie Rossiiskoi Akademii Nauk Institut Molekulyarnoi Biologii Im. V.A. Engelgardta Ran (Imb Ran) | Method for identifying the genotype and subtype of hepatitis c virus on a biological microchip |
| US8601526B2 (en) | 2008-06-13 | 2013-12-03 | United Video Properties, Inc. | Systems and methods for displaying media content and media guidance information |
| US8258283B2 (en) * | 2008-12-29 | 2012-09-04 | Lg Life Sciences Ltd. | Method for detection of HCV at the real time PCR with intercalating dye |
| US20100240049A1 (en) * | 2009-01-16 | 2010-09-23 | Cepheid | Methods of Detecting Cervical Cancer |
| EP2379752B1 (en) | 2009-01-19 | 2015-09-30 | Biomérieux S.A. | Methods for determining the susceptibility of a subject to contract a nosocomial infection and for establishing a prognose of evolution of septic syndrome |
| US20100323344A1 (en) * | 2009-06-18 | 2010-12-23 | Ferguson Monique R | Detection of hepatitis C virus RNA |
| US9204193B2 (en) | 2010-05-14 | 2015-12-01 | Rovi Guides, Inc. | Systems and methods for media detection and filtering using a parental control logging application |
| WO2011150976A1 (en) | 2010-06-04 | 2011-12-08 | bioMérieux | Method and kit for the prognosis of colorectal cancer |
| US9110079B2 (en) | 2010-09-29 | 2015-08-18 | Biomerieux | Method and kit for establishing an in vitro prognosis on a patient exhibiting SIRS |
| FR2970975B1 (en) | 2011-01-27 | 2016-11-04 | Biomerieux Sa | METHOD AND KIT FOR DETERMINING IN VITRO THE IMMUNE STATUS OF AN INDIVIDUAL |
| WO2012129758A1 (en) | 2011-03-25 | 2012-10-04 | Biomerieux | Method and kit for determining in vitro probability for individual to suffer from colorectal cancer |
| ES2640570T3 (en) * | 2012-10-18 | 2017-11-03 | F. Hoffmann-La Roche Ag | Double probe assay for HCV detection |
| FR3000966B1 (en) | 2013-01-11 | 2016-10-28 | Biomerieux Sa | METHOD FOR ESTABLISHING IN VITRO A PROGNOSIS OF SEVERITY IN A SEPTIC SHOCK PATIENT |
| CN104178562B (en) | 2013-05-21 | 2018-11-09 | 生物梅里埃股份公司 | A kind of colorectal cancer prognosis kit |
| EP3529381B1 (en) * | 2016-10-19 | 2022-07-06 | Gen-Probe Incorporated | Compositions and methods for detecting or quantifying hepatitis c virus |
| EP3643792B1 (en) | 2018-10-24 | 2021-09-15 | Fujirebio Europe N.V. | Detection and analysis of sequence variations in a target nucleic acid |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8810400D0 (en) * | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| JPH02167081A (en) * | 1988-12-21 | 1990-06-27 | Tetsuo Nakamura | Genome rna of hepatitis virus of non-a, non-b type, cdna and viral antigen protein |
| US5176994A (en) * | 1988-12-21 | 1993-01-05 | Immuno Japan Inc. | Non-A, Non-B hepatitis virus genome RNA, cDNA and virus antigen protein |
| US5629158A (en) | 1989-03-22 | 1997-05-13 | Cemu Bitecknik Ab | Solid phase diagnosis of medical conditions |
| US5043272A (en) * | 1989-04-27 | 1991-08-27 | Life Technologies, Incorporated | Amplification of nucleic acid sequences using oligonucleotides of random sequence as primers |
| JP2802125B2 (en) * | 1989-06-23 | 1998-09-24 | キヤノン株式会社 | Nucleic acid detection method |
| US5372928A (en) * | 1989-09-15 | 1994-12-13 | Chiron Corporation | Hepatitis C virus isolates |
| GB8924989D0 (en) * | 1989-11-06 | 1989-12-28 | Scotgen Ltd | Method and device for the detection of antibiotic resistance |
| US5252743A (en) * | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
| US5629153A (en) * | 1990-01-10 | 1997-05-13 | Chiron Corporation | Use of DNA-dependent RNA polymerase transcripts as reporter molecules for signal amplification in nucleic acid hybridization assays |
| CA2044296A1 (en) * | 1990-06-12 | 1991-12-13 | Hiroaki Okamoto | Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus |
| DK0469348T3 (en) * | 1990-07-11 | 1997-04-01 | Shionogi & Co | cDNA sequence and detection of hepatitis C virus |
| HUT69140A (en) * | 1990-08-10 | 1995-08-28 | Chiron Corp | Nanbv diagnostics: polynucleotides useful for screening for hepatitis c virus |
| US5620852A (en) | 1990-11-14 | 1997-04-15 | Hri Research, Inc. | Nucleic acid preparation methods |
| EP0834576B1 (en) * | 1990-12-06 | 2002-01-16 | Affymetrix, Inc. (a Delaware Corporation) | Detection of nucleic acid sequences |
| EP0511559A1 (en) * | 1991-04-30 | 1992-11-04 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Oligonucleotide probe reagent |
| US6190864B1 (en) | 1991-05-08 | 2001-02-20 | Chiron Corporation | HCV genomic sequences for diagnostics and therapeutics |
| CZ288720B6 (en) | 1991-05-08 | 2001-08-15 | Chiron Corporation | Nucleic acid, composition containing thereof, method of forming a hybridization product and HCV genotype detection method |
| US5428145A (en) * | 1991-08-09 | 1995-06-27 | Immuno Japan, Inc. | Non-A, non-B, hepatitis virus genome, polynucleotides, polypeptides, antigen, antibody and detection systems |
| ES2198514T3 (en) * | 1991-08-27 | 2004-02-01 | F. Hoffmann-La Roche Ag | PRIMERS AND PROBES FOR THE DETECTION OF HEPATITIS C. |
| EP0532258A2 (en) * | 1991-09-09 | 1993-03-17 | Immuno Japan Inc. | Oligonucleotides and determination system of HCV genotypes |
| JPH06502770A (en) | 1991-09-12 | 1994-03-31 | シーダーズ−サイナイ・メディカル・センター | Direct detection method for hepatitis C virus RNA |
| US5173994A (en) * | 1992-01-14 | 1992-12-29 | The United States Of America As Represented By The Secretary Of Agriculture | Fiber cleaning apparatus with air flow deflector |
| JPH08500481A (en) * | 1992-05-11 | 1996-01-23 | リボザイム・ファーマシューティカルズ・インコーポレーテッド | Methods and agents for inhibiting viral replication |
| DK0637342T3 (en) * | 1992-11-27 | 1999-11-01 | Innogenetics Nv | Method for typing HCV isolates |
| JPH06153961A (en) | 1992-11-27 | 1994-06-03 | Imuno Japan:Kk | Partial gene of hepatitis c virus and method for detecting gene of hepatitis c virus in high sensitivity |
| US5820852A (en) * | 1996-11-26 | 1998-10-13 | The Proctor & Gamble Company | Oral compositions containing fluoride, pyrophosphate, and peroxide |
-
1993
- 1993-11-26 DK DK94901891T patent/DK0637342T3/en active
- 1993-11-26 EP EP01121347A patent/EP1197568B1/en not_active Expired - Lifetime
- 1993-11-26 DE DE69324678T patent/DE69324678T2/en not_active Expired - Lifetime
- 1993-11-26 ES ES94901891T patent/ES2133529T3/en not_active Expired - Lifetime
- 1993-11-26 US US08/256,568 patent/US5846704A/en not_active Expired - Lifetime
- 1993-11-26 CA CA2128528A patent/CA2128528C/en not_active Expired - Lifetime
- 1993-11-26 DE DE69334357T patent/DE69334357D1/en not_active Expired - Lifetime
- 1993-11-26 SG SG1996004862A patent/SG46456A1/en unknown
- 1993-11-26 WO PCT/EP1993/003325 patent/WO1994012670A2/en active IP Right Grant
- 1993-11-26 AT AT94901891T patent/ATE179459T1/en active
- 1993-11-26 EP EP98117538A patent/EP0905258A3/en not_active Withdrawn
- 1993-11-26 AT AT01121347T patent/ATE507312T1/en not_active IP Right Cessation
- 1993-11-26 AU AU56282/94A patent/AU681612B2/en not_active Expired
- 1993-11-26 JP JP51276794A patent/JP4251407B2/en not_active Expired - Lifetime
- 1993-11-26 EP EP94901891A patent/EP0637342B1/en not_active Expired - Lifetime
-
1998
- 1998-03-10 US US09/038,369 patent/US6171784B1/en not_active Expired - Lifetime
- 1998-03-19 US US09/044,665 patent/US6051696A/en not_active Expired - Lifetime
-
1999
- 1999-06-30 GR GR990401727T patent/GR3030641T3/en unknown
- 1999-08-23 US US09/378,900 patent/US6495670B1/en not_active Expired - Fee Related
-
2001
- 2001-07-06 US US09/899,044 patent/US6548244B2/en not_active Expired - Fee Related
- 2001-07-06 US US09/899,082 patent/US6891026B2/en not_active Expired - Fee Related
- 2001-07-06 US US09/899,302 patent/US6887985B2/en not_active Expired - Fee Related
-
2002
- 2002-10-17 HK HK02107543.5A patent/HK1047961A1/en unknown
-
2004
- 2004-04-13 US US10/822,711 patent/US7258982B2/en not_active Expired - Fee Related
- 2004-11-11 JP JP2004328242A patent/JP2005040145A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2128528A1 (en) | Process for typing of hcv isolates | |
| US5283171A (en) | Compositions for and detection of human papillomavirus by specific oligonucleotide polymerase primers using the polymerase chain reaction | |
| EP0915991B1 (en) | Nucleic acid amplification method based on ramification-extension (ram) and in vitro transcription | |
| US6376191B1 (en) | Microarray-based analysis of polynucleotide sequence variations | |
| US20050084851A1 (en) | Method | |
| EP0566670A1 (en) | Nucleic acid sequence detection by triple helix formation | |
| CA2479045C (en) | Amplification-hybridisation method for detecting and typing human papillomavirus | |
| CA2321654C (en) | Oligonucleotides for the amplification and detection of epstein barr virus (ebv) nucleic acid | |
| US8222389B2 (en) | Method for lowering both sequence variations and increase of base line effects in a diagnostic hybridisation assay, assay for performing such a method and probe for use in the assay | |
| WO1990011374A1 (en) | Polymerase chain reaction products incorporating reporter moieties and affinity seperation | |
| EP1373575A2 (en) | Methods for detection of human papillomavirus mrna | |
| Kostrikis et al. | Genotyping HIV-1 and HCV strains by a combinatorial DNA melting assay (COMA) | |
| Narayanan | Concepts, principles, and applications of selected molecular biology techniques in clinical biochemistry | |
| EP3458603A1 (en) | Penta e polymorphisms for human identification | |
| CA2024978A1 (en) | Nucleic acid detection method using unequal primer concentrations in polymerase chain reaction | |
| Castelain et al. | Direct blotting electrophoresis for sequencing and genotyping hepatitis C virus | |
| Käller et al. | Tag-array based HPV genotyping by competitive hybridization and extension | |
| JP2024034944A (en) | Hybridization buffer composition and hybridization method | |
| Torfason et al. | Global Identification of Three Major | |
| Antson | Genotyping RNA and DNA using padlock probes | |
| Erasmus et al. | Basics of molecular biology and its applications-III. Polymerase chain reaction and in situ hybridization | |
| JPH1023894A (en) | Detection of plural kinds of nucleic acids in specimen | |
| EP0465557A1 (en) | Process for rapid nucleic acid detection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20131126 |